author-photo

Shuyan Du

Bristol-Myers Squibb

15

Papers

395

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.

2021 Hepatology
Show All
- Source
- Cite
- Save
Citations (0)
The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis

2021 Contemporary Clinical Trials
Show All
- Source
- Cite
- Save
Citations (3)
1910PRadiomic signatures for identification of tumors sensitive to nivolumab or docetaxel in squamous non-small cell lung cancer (sqNSCLC)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Whole body PD-L1 PET in patients with NSCLC and melanoma.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

2018 Nature Communications
Show All
- Source
- Cite
- Save
Citations (167)
Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils

2016 Cell Metabolism
Show All
- Source
- Cite
- Save
Citations (79)
The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: A multicenter FDG- PET trial

2015 Atherosclerosis
Show All
- Source
- Cite
- Save
Citations (54)
Design and synthesis of [18F]-BMT-083133 as a potential PET radioligand for the lysophosphatidic acid receptor 1 (LPA1)

2014 The Journal of Nuclear Medicine
Show All
- Source
- Cite
- Save
Citations (0)
Development of a lysophosphatidic acid receptor 1 (LPA1) radioligand for lung imaging with PET

2014 The Journal of Nuclear Medicine
Show All
- Source
- Cite
- Save
Citations (2)